MannKind (MNKD)
Market Price (3/15/2026): $2.78 | Market Cap: $854.2 MilSector: Health Care | Industry: Biotechnology
MannKind (MNKD)
Market Price (3/15/2026): $2.78Market Cap: $854.2 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -54% | Weak multi-year price returns2Y Excs Rtn is -80%, 3Y Excs Rtn is -112% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 22x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 47x, P/EPrice/Earnings or Price/(Net Income) is 145x |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Diabetes Management, Targeted Therapies, Show more. | Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.3% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -54% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Diabetes Management, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -80%, 3Y Excs Rtn is -112% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 22x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 47x, P/EPrice/Earnings or Price/(Net Income) is 145x |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.3% |
Qualitative Assessment
AI Analysis | Feedback
MannKind (MNKD) stock has lost about 50% since 11/30/2025 because of the following key factors:
1. Deterioration in Q4 2025 Profitability Despite Revenue Growth. MannKind reported its Fourth Quarter 2025 financial results on February 26, 2026, posting an earnings per share (EPS) of -$0.05, missing the consensus estimate of -$0.01 by $0.04. The company also experienced a net loss of $15.9 million for Q4 2025, a significant decline from a net income of $7.4 million in Q4 2024. This profitability setback occurred despite a 45.8% year-over-year increase in quarterly revenue to $111.96 million, which exceeded analyst expectations. The shift to a net loss was primarily driven by substantial increases in operating expenses, including a 148% rise in research and development (R&D) expenses and a 144% increase in selling, general, and administrative (SG&A) expenses compared to the same period in the prior year.
2. Intensified Concerns Over United Therapeutics' Competition to Tyvaso DPI Royalties. A significant factor contributing to investor apprehension was the increased focus on potential competition to MannKind's royalty stream from United Therapeutics' (UT) Tyvaso DPI. While MannKind has been diversifying its portfolio, it still relies on these royalties. Concerns heightened during this period as United Therapeutics is developing its own soft mist treprostinil inhaler, which could directly compete with Tyvaso DPI. This potential rivalry from a key partner challenges MannKind's narrative of decreasing reliance on UT-related revenues and introduces uncertainty regarding the long-term stability and growth of a crucial income source.
Show more
1. Deterioration in Q4 2025 Profitability Despite Revenue Growth. MannKind reported its Fourth Quarter 2025 financial results on February 26, 2026, posting an earnings per share (EPS) of -$0.05, missing the consensus estimate of -$0.01 by $0.04. The company also experienced a net loss of $15.9 million for Q4 2025, a significant decline from a net income of $7.4 million in Q4 2024. This profitability setback occurred despite a 45.8% year-over-year increase in quarterly revenue to $111.96 million, which exceeded analyst expectations. The shift to a net loss was primarily driven by substantial increases in operating expenses, including a 148% rise in research and development (R&D) expenses and a 144% increase in selling, general, and administrative (SG&A) expenses compared to the same period in the prior year.
2. Intensified Concerns Over United Therapeutics' Competition to Tyvaso DPI Royalties. A significant factor contributing to investor apprehension was the increased focus on potential competition to MannKind's royalty stream from United Therapeutics' (UT) Tyvaso DPI. While MannKind has been diversifying its portfolio, it still relies on these royalties. Concerns heightened during this period as United Therapeutics is developing its own soft mist treprostinil inhaler, which could directly compete with Tyvaso DPI. This potential rivalry from a key partner challenges MannKind's narrative of decreasing reliance on UT-related revenues and introduces uncertainty regarding the long-term stability and growth of a crucial income source.
Show more
Stock Movement Drivers
Fundamental Drivers
The -48.2% change in MNKD stock from 11/30/2025 to 3/13/2026 was primarily driven by a -82.0% change in the company's Net Income Margin (%).| (LTM values as of) | 11302025 | 3132026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.35 | 2.77 | -48.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 314 | 349 | 11.2% |
| Net Income Margin (%) | 9.3% | 1.7% | -82.0% |
| P/E Multiple | 56.1 | 145.2 | 158.6% |
| Shares Outstanding (Mil) | 307 | 307 | -0.2% |
| Cumulative Contribution | -48.2% |
Market Drivers
11/30/2025 to 3/13/2026| Return | Correlation | |
|---|---|---|
| MNKD | -48.2% | |
| Market (SPY) | -3.1% | 0.2% |
| Sector (XLV) | -5.0% | 14.9% |
Fundamental Drivers
The -39.7% change in MNKD stock from 8/31/2025 to 3/13/2026 was primarily driven by a -84.5% change in the company's Net Income Margin (%).| (LTM values as of) | 8312025 | 3132026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.59 | 2.77 | -39.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 302 | 349 | 15.7% |
| Net Income Margin (%) | 10.9% | 1.7% | -84.5% |
| P/E Multiple | 42.7 | 145.2 | 240.2% |
| Shares Outstanding (Mil) | 305 | 307 | -0.8% |
| Cumulative Contribution | -39.7% |
Market Drivers
8/31/2025 to 3/13/2026| Return | Correlation | |
|---|---|---|
| MNKD | -39.7% | |
| Market (SPY) | 3.0% | 8.5% |
| Sector (XLV) | 9.5% | 13.8% |
Fundamental Drivers
The -48.1% change in MNKD stock from 2/28/2025 to 3/13/2026 was primarily driven by a -82.6% change in the company's Net Income Margin (%).| (LTM values as of) | 2282025 | 3132026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.34 | 2.77 | -48.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 286 | 349 | 22.2% |
| Net Income Margin (%) | 9.7% | 1.7% | -82.6% |
| P/E Multiple | 54.0 | 145.2 | 168.6% |
| Shares Outstanding (Mil) | 279 | 307 | -9.1% |
| Cumulative Contribution | -48.1% |
Market Drivers
2/28/2025 to 3/13/2026| Return | Correlation | |
|---|---|---|
| MNKD | -48.1% | |
| Market (SPY) | 12.4% | 15.3% |
| Sector (XLV) | 1.9% | 23.1% |
Fundamental Drivers
The -47.5% change in MNKD stock from 2/28/2023 to 3/13/2026 was primarily driven by a -82.5% change in the company's P/S Multiple.| (LTM values as of) | 2282023 | 3132026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.28 | 2.77 | -47.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 100 | 349 | 249.8% |
| P/S Multiple | 13.9 | 2.4 | -82.5% |
| Shares Outstanding (Mil) | 263 | 307 | -14.3% |
| Cumulative Contribution | -47.5% |
Market Drivers
2/28/2023 to 3/13/2026| Return | Correlation | |
|---|---|---|
| MNKD | -47.5% | |
| Market (SPY) | 73.4% | 21.3% |
| Sector (XLV) | 23.3% | 26.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| MNKD Return | 40% | 21% | -31% | 77% | -12% | -50% | -10% |
| Peers Return | 9% | -9% | 4% | -11% | 10% | -7% | -7% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -1% | 80% |
Monthly Win Rates [3] | |||||||
| MNKD Win Rate | 50% | 50% | 50% | 67% | 50% | 33% | |
| Peers Win Rate | 52% | 50% | 55% | 43% | 50% | 53% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| MNKD Max Drawdown | 0% | -40% | -37% | -11% | -47% | -54% | |
| Peers Max Drawdown | -11% | -23% | -19% | -26% | -19% | -12% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -2% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ACT, ALKS, LIVN, PRGO, PCRX. See MNKD Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/13/2026 (YTD)
How Low Can It Go
| Event | MNKD | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -57.3% | -25.4% |
| % Gain to Breakeven | 134.2% | 34.1% |
| Time to Breakeven | 913 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -52.2% | -33.9% |
| % Gain to Breakeven | 109.2% | 51.3% |
| Time to Breakeven | 93 days | 148 days |
| 2018 Correction | ||
| % Loss | -84.9% | -19.8% |
| % Gain to Breakeven | 564.4% | 24.7% |
| Time to Breakeven | 2,263 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -88.3% | -56.8% |
| % Gain to Breakeven | 753.5% | 131.3% |
| Time to Breakeven | Not Fully Recovered days | 1,480 days |
Compare to ACT, ALKS, LIVN, PRGO, PCRX
In The Past
MannKind's stock fell -57.3% during the 2022 Inflation Shock from a high on 2/19/2021. A -57.3% loss requires a 134.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About MannKind (MNKD)
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
AI Analysis | Feedback
- The Eli Lilly of inhaled insulin.
- The Dyson of inhaled drug delivery.
- Like a specialized Vertex Pharmaceuticals, but focused on inhaled treatments for endocrine and orphan lung diseases.
AI Analysis | Feedback
- Afrezza: An inhaled insulin used to improve glycemic control in adults with diabetes.
- Thyquidity: A product promoted for the treatment of hypothyroidism.
- ZYESAMI (aviptadil): A dry powder formulation under development in collaboration with NRx Pharmaceuticals to help protect cells against inflammatory conditions.
AI Analysis | Feedback
MannKind Corporation (MNKD) sells its products primarily to other companies within the healthcare supply chain and through strategic collaborations. Its major customers include:
-
Pharmaceutical Wholesalers: These companies are the primary direct purchasers of MannKind’s commercial products, such as Afrezza and Thyquidity, for distribution to pharmacies, hospitals, and other healthcare providers. The largest pharmaceutical wholesalers in the United States, which typically serve as major customers for biopharmaceutical companies, include:
- McKesson Corporation (MCK)
- Cardinal Health, Inc. (CAH)
- AmerisourceBergen Corporation (ABC)
- United Therapeutics Corporation (UTHR): As per the company description, MannKind has a license and collaboration agreement with United Therapeutics Corporation. This agreement indicates that United Therapeutics is a significant partner and customer for licensed products or services related to their collaboration.
- NRx Pharmaceuticals (NRXP): MannKind has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI. This type of development agreement often involves payments for services or future product supply, making NRx Pharmaceuticals a customer in this context.
AI Analysis | Feedback
```html- United Therapeutics Corporation (UTHR)
- Bachem AG (BANB)
- Dr. Reddy's Laboratories Ltd. (RDY)
AI Analysis | Feedback
nullAI Analysis | Feedback
nullAI Analysis | Feedback
null
AI Analysis | Feedback
nullAI Analysis | Feedback
nullAI Analysis | Feedback
nullLatest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| MannKind Earnings Notes | 12/16/2025 | |
| Can MannKind Stock Hold Up When Markets Turn? | 10/17/2025 | |
| MannKind (MNKD) Revenue Comparison | 08/08/2025 | |
| MannKind (MNKD) Net Income Comparison | 08/08/2025 | |
| MannKind (MNKD) Operating Cash Flow Comparison | 08/08/2025 | |
| MannKind (MNKD) Operating Income Comparison | 08/08/2025 | |
| MannKind (MNKD) Debt Comparison | 08/08/2025 | |
| MannKind (MNKD) EBITDA Comparison | 08/08/2025 | |
| MannKind (MNKD) Tax Expense Comparison | 08/08/2025 | |
| Why MannKind Stock Moved: MNKD Stock Has Gained 60% Since 2023 Fiscal End, Primarily Due To Favorable Change In Revenues | 08/08/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to MNKD.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 25.51 |
| Mkt Cap | 2.2 |
| Rev LTM | 1,312 |
| Op Inc LTM | 199 |
| FCF LTM | 159 |
| FCF 3Y Avg | 191 |
| CFO LTM | 246 |
| CFO 3Y Avg | 253 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 3.2% |
| Rev Chg 3Y Avg | 7.4% |
| Rev Chg Q | 4.4% |
| QoQ Delta Rev Chg LTM | 1.1% |
| Op Mgn LTM | 13.3% |
| Op Mgn 3Y Avg | 10.5% |
| QoQ Delta Op Mgn LTM | -3.7% |
| CFO/Rev LTM | 19.6% |
| CFO/Rev 3Y Avg | 18.4% |
| FCF/Rev LTM | 15.6% |
| FCF/Rev 3Y Avg | 15.3% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 2.2 |
| P/S | 2.4 |
| P/EBIT | 10.8 |
| P/E | 13.8 |
| P/CFO | 8.4 |
| Total Yield | 0.7% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 8.0% |
| D/E | 0.3 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -16.2% |
| 3M Rtn | -9.2% |
| 6M Rtn | -5.7% |
| 12M Rtn | -7.5% |
| 3Y Rtn | -11.6% |
| 1M Excs Rtn | -13.9% |
| 3M Excs Rtn | -6.6% |
| 6M Excs Rtn | -9.7% |
| 12M Excs Rtn | -26.7% |
| 3Y Excs Rtn | -84.8% |
FDA Approved Drugs Data
Expand for More| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| BLA022472 | AFREZZA | insulin recombinant human | powder | 6272014 | -39.0% | -43.4% | -41.8% | -87.5% | -94.5% |
Price Behavior
Price Behavior
| Market Price | $2.77 | |
| Market Cap ($ Bil) | 0.8 | |
| First Trading Date | 07/28/2004 | |
| Distance from 52W High | -55.4% | |
| 50 Days | 200 Days | |
| DMA Price | $4.97 | $4.84 |
| DMA Trend | indeterminate | down |
| Distance from DMA | -44.2% | -42.8% |
| 3M | 1YR | |
| Volatility | 90.6% | 66.4% |
| Downside Capture | 156.97 | 97.14 |
| Upside Capture | -303.54 | 13.98 |
| Correlation (SPY) | -0.8% | 15.0% |
MNKD Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.86 | -0.66 | -0.61 | -0.03 | 0.49 | 0.76 |
| Up Beta | -0.30 | 0.94 | 0.08 | 0.31 | 0.39 | 0.49 |
| Down Beta | 1.26 | -1.01 | -1.08 | 0.52 | 0.52 | 0.77 |
| Up Capture | -530% | -297% | -188% | -63% | 15% | 41% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 10 | 20 | 28 | 57 | 115 | 348 |
| Down Capture | 204% | 122% | 74% | -0% | 89% | 103% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 11 | 20 | 28 | 58 | 124 | 372 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MNKD | |
|---|---|---|---|---|
| MNKD | -45.8% | 66.4% | -0.63 | - |
| Sector ETF (XLV) | 5.0% | 17.5% | 0.12 | 23.9% |
| Equity (SPY) | 19.6% | 18.9% | 0.81 | 15.0% |
| Gold (GLD) | 71.9% | 26.3% | 2.05 | 7.6% |
| Commodities (DBC) | 19.3% | 17.3% | 0.89 | 1.1% |
| Real Estate (VNQ) | 6.2% | 16.3% | 0.19 | 11.0% |
| Bitcoin (BTCUSD) | -15.3% | 44.2% | -0.25 | 4.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MNKD | |
|---|---|---|---|---|
| MNKD | -4.8% | 59.6% | 0.16 | - |
| Sector ETF (XLV) | 7.5% | 14.5% | 0.33 | 30.3% |
| Equity (SPY) | 13.1% | 17.0% | 0.61 | 31.1% |
| Gold (GLD) | 24.1% | 17.3% | 1.14 | 8.6% |
| Commodities (DBC) | 11.2% | 19.0% | 0.47 | 6.6% |
| Real Estate (VNQ) | 4.8% | 18.8% | 0.16 | 28.1% |
| Bitcoin (BTCUSD) | 6.3% | 56.7% | 0.33 | 13.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MNKD | |
|---|---|---|---|---|
| MNKD | -7.0% | 84.9% | 0.28 | - |
| Sector ETF (XLV) | 10.1% | 16.5% | 0.50 | 21.5% |
| Equity (SPY) | 14.5% | 17.9% | 0.70 | 22.6% |
| Gold (GLD) | 14.4% | 15.6% | 0.77 | 4.4% |
| Commodities (DBC) | 8.6% | 17.6% | 0.40 | 8.8% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.23 | 17.9% |
| Bitcoin (BTCUSD) | 67.4% | 66.8% | 1.07 | 9.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/26/2026 | -7.4% | -15.7% | |
| 11/5/2025 | 10.6% | -4.2% | 3.6% |
| 8/6/2025 | -13.2% | -8.3% | 33.8% |
| 5/8/2025 | -4.5% | -5.8% | -9.7% |
| 2/26/2025 | -4.4% | -5.9% | -6.8% |
| 11/7/2024 | -0.6% | -5.0% | -9.9% |
| 8/7/2024 | -4.9% | -3.8% | 14.4% |
| 5/8/2024 | -2.0% | 1.1% | 6.1% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 10 | 13 |
| # Negative | 13 | 14 | 10 |
| Median Positive | 4.9% | 11.1% | 17.8% |
| Median Negative | -4.5% | -6.9% | -9.8% |
| Max Positive | 18.5% | 35.3% | 42.5% |
| Max Negative | -13.2% | -39.5% | -37.5% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/26/2026 | 10-K |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 02/26/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 02/27/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/07/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 02/23/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| 03/31/2022 | 05/05/2022 | 10-Q |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Castagna, Michael | Chief Executive Officer | Direct | Sell | 12192025 | 6.01 | 65,804 | 395,482 | 15,053,800 | Form |
| 2 | Castagna, Michael | Chief Executive Officer | Direct | Sell | 12162025 | 6.00 | 20,806 | 124,836 | 15,028,752 | Form |
| 3 | Castagna, Michael | Chief Executive Officer | Direct | Sell | 12162025 | 6.00 | 21,310 | 127,860 | 15,028,752 | Form |
| 4 | Castagna, Michael | Chief Executive Officer | Direct | Sell | 12042025 | 5.57 | 107,920 | 601,114 | 13,951,691 | Form |
| 5 | Thomson, David | EVP Genl Counsel & Secretary | Direct | Sell | 12042025 | 5.57 | 147,780 | 823,135 | 4,688,375 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.